Teva Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals

TEVA 31.51

-1.2%

11:53 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dorine Essey who wrote (262)	7/31/2000 2:28:13 PM
From: Dorine Essey	Read Replies (1) of 340

Teva Pharmaceutical Industries Ltd. (TEVA) today reported that net income (before one-time charges) for the quarter ended June 30, 2000, reached $44.7 million compared with $31.1 million reported in the second quarter of 1999 (up 44%) and earnings per ADR (before a one-time charge) were $0.33 (up 32%). Total sales for the second quarter 2000 rose 51% to 444.0 million. 59% of these sales were in North America, 24% in Europe, 14% in Israel and 3% in the rest of world. The one-time charge relates to the purchase of in-process R&D, in the amount of $35.7 million, mainly due to the acquisition of Novopharm. Including this one-time charge, net income for the quarter totaled $9.0 million and earnings per ADR amounted to $0.06.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next